GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (OTCPK:HLNCF) » Definitions » Asset Impairment Charge

HLNCF (Haleon) Asset Impairment Charge : $0 Mil (TTM As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Haleon Asset Impairment Charge?

Haleon's Asset Impairment Charge for the three months ended in Jun. 2024 was $0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was $0 Mil.

Haleon Asset Impairment Charge Historical Data

The historical data trend for Haleon's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haleon Asset Impairment Charge Chart

Haleon Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Impairment Charge
- - - - -

Haleon Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Haleon Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

Haleon Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Haleon's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Haleon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Haleon PLC (OTCPK:HLNCF) » Definitions » Asset Impairment Charge
Comparable Companies
LSE:HIK LSE:HCM LSE:INDV LSE:BMK LSE:APH LSE:ANCR LSE:EAH LSE:AGY LSE:CEL LSE:STX ZTS XTER:MRK TSE:4502 NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692 NBIX
Traded in Other Exchanges
HLN:USA HLNl:UK HLN:UK H6D0:Germany
Address
The Heights, Building 5, First Floor, Surrey, Weybridge, GBR, KT13 0NY
Website
https://www.haleon.com
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.